ML + metabolomics in the clinic: promise vs reality 🧠🧬

A critical review of machine learning-based clinical decision support systems built on metabolomics data, highlighting opportunities, pitfalls, and future directions.

Keywords

metabolomics, machine learning, clinical decision support, CDSS, biomarkers, precision medicine, AI

---

📌 Project highlights

• 🧠 Machine learning for clinical decision support systems (CDSS)
  
• 🧬 Focus on metabolomics data complexity
  
• ⚙️ Covers full pipeline: data → models → clinical utility
  
• ⚠️ Critical discussion of limitations & risks
  
• 🚀 Outlook on precision medicine applications

---

🎉 New review out! This one sits at the intersection of AI, metabolomics and clinical practice

🔗 Explore the paper

• 📚 Paper (TRAC) or pdf

👉 A deep dive into how machine learning turns metabolomics into clinical decisions.

---

🎧 Audio summary

Not everyone wants to dive straight into ML, metabolomics, and clinical pipelines (fair 😄)

👉 Here’s a short audio walkthrough 🎧 explaining what this work is about and why it matters:

🔬 What is this about?

Modern medicine generates massive, multi-layered datasets.

Among them:

👉 metabolomics captures the current physiological state of a patient

• fast response to environmental changes
  
• extremely high chemical diversity
  
• thousands of measurable molecules

But this comes at a cost:

❗ extreme complexity → requires machine learning

---

🧠 Enter: Clinical Decision Support Systems (CDSS)

ML-based CDSS aim to:

• diagnose diseases
  
• predict outcomes
  
• guide treatment decisions

👉 essentially simulate clinical reasoning using data

Typical pipeline:

1. 🧪 Sample collection (blood, urine, tissue)
   
2. 🔬 MS / NMR → metabolite profiles
   
3. 📊 Data processing
   
4. 🤖 ML model → prediction

📊 The diagram on page 3 shows this full workflow clearly:

• raw spectra → metabolites → clinical data → predictive model

---

⚙️ Machine learning in metabolomics

Three main paradigms:

🔍 Unsupervised learning

• clustering patients/metabolites
  
• dimensionality reduction (PCA, etc.)

🎯 Supervised learning

• classification (disease vs control)
  
• regression (risk prediction)

⏳ Specialized models

• survival analysis
  
• time-to-event predictions

👉 ML is already deeply embedded, even in metabolite identification pipelines.

---

⚠️ Core challenge: the data itself

Metabolomics is… messy.

1. Curse of dimensionality

• thousands of metabolites
  
• few samples (“p ≫ n”)
  
• risk of overfitting

2. Noise & artifacts

• MS produces thousands of signals
  
• many are:
  • background noise
    
  • adducts / fragments
    
  • misannotations

👉 can completely distort ML models

3. Missing values

• technical + biological causes
  
• require complex imputation strategies

---

🧬 Feature selection & engineering

To survive this complexity, models rely on:

✂️ Feature selection

• filter (statistics)
  
• wrapper (model-based)
  
• embedded (e.g., LASSO, RF)

🔄 Feature engineering

• normalization
  
• scaling
  
• pathway-based aggregation

👉 This step is absolutely critical for model performance

---

📊 Clinical evaluation ≠ ML accuracy

This is one of the most important points.

👉 High accuracy ≠ clinical usefulness

Instead, models must optimize:

• sensitivity / specificity
  
• false positives vs false negatives
  
• clinical utility metrics (NB, NNB)

👉 because wrong predictions have real consequences

---

🧠 Explainability problem

Many models are:

❌ black boxes

This is unacceptable in medicine.

👉 Enter XAI (Explainable AI)
- helps understand decisions
- validates biological plausibility
- builds trust

---

🔗 Pathway analysis as validation

A really nice idea in this paper:

👉 use pathway analysis as an independent check

• confirms biological relevance
  
• links metabolites → mechanisms

Example:

• Parkinson’s biomarkers
  
• validated via pathway links to α-synuclein aggregation

---

🚨 Reality check: current limitations

Despite hype, major issues remain:

• ❌ lack of external validation
  
• ❌ small, biased datasets
  
• ❌ poor reproducibility
  
• ❌ limited interpretability

👉 many models are not clinically ready yet

---

🧠 Deeper problem: causality

ML finds patterns—but:

👉 correlation ≠ causation

To personalize treatment, we need:

• causal inference
  
• mechanistic understanding
  
• integration with biology

---

🚀 Why this matters

This review makes one thing clear:

👉 metabolomics + ML is powerful
👉 but not plug-and-play

Future progress depends on:

• better data quality
  
• standardized pipelines
  
• integration with clinical data
  
• rigorous validation

---

💚 BioGenies perspective

This fits perfectly with what we care about:

• data quality 🧪
  
• model interpretability 🧠
  
• biological grounding 🔬

👉 because good models need good biology—not just good ML